Trials / Conditions / Refractory Chronic Myelomonocytic Leukemia

Refractory Chronic Myelomonocytic Leukemia

19 registered clinical trials studyying Refractory Chronic Myelomonocytic Leukemia — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Recruiting	A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034	Solu Therapeutics, Inc	Phase 1
Recruiting	Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Ne NCT06523556	Uma Borate	Phase 1 / Phase 2
Recruiting	Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic S NCT05549661	Mayo Clinic	Phase 1
Completed	Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who NCT05030675	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies NCT04891757	Foghorn Therapeutics Inc.	Phase 1
Terminated	DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or C NCT04550442	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patien NCT04239157	M.D. Anderson Cancer Center	Phase 2
Completed	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or NCT04487106	M.D. Anderson Cancer Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Recruiting	Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute My NCT04140487	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomo NCT03896269	M.D. Anderson Cancer Center	Phase 1
Completed	A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies NCT03886831	Prelude Therapeutics	Phase 1
Active Not Recruiting	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034	M.D. Anderson Cancer Center	Phase 1
Terminated	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193	M.D. Anderson Cancer Center	Phase 2
Completed	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leuk NCT01892371	M.D. Anderson Cancer Center	Phase 1 / Phase 2